SCHEMBL6797047

SCHEMBL6797047

O=c1c(Cc2ccccc2)nc2cccnc2n1-c1cccc(NC(=S)Nc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.49
BTK Q06187 1/20 0.49
ITK Q08881 1/20 0.49
MMP9 P14780 2/20 0.48
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
TP53 P04637 4/20 0.41
MAPT P10636 3/20 0.41
KDR P35968 1/20 0.41
AKT1 P31749 2/20 0.41
AKT2 P31751 1/20 0.41
AKT3 Q9Y243 1/20 0.41
ALDH1A1 P00352 3/20 0.40
USP2 O75604 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
TSHR P16473 2/20 0.39
CYP2C19 P33261 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804102 0.92 GAA (0.48) EGFRBTKITKMMP9MAOA
SCHEMBL6794031 0.91 EGFR (0.51) EGFRBTKITKMMP9MAOA
SCHEMBL6796133 0.90 ALDH1A1 (0.50) EGFRBTKITKMMP9MAOA
SCHEMBL6797247 0.89 EGFR (0.53) EGFRBTKITKTP53MAPT
SCHEMBL6801055 0.89 EGFR (0.51) EGFRBTKITKMMP9MAOA
SCHEMBL6802886 0.88 EGFR (0.49) EGFRBTKITKMMP9MAOA
SCHEMBL6792958 0.88 AKT1 (0.50) EGFRBTKITKTP53MAPT
SCHEMBL6797876 0.87 EGFR (0.48) EGFRBTKITKTP53MAPT
SCHEMBL6793474 0.87 EGFR (0.51) EGFRBTKITKTP53MAPT
SCHEMBL6805022 0.86 EGFR (0.51) EGFRBTKITKTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 EGFR 419/4885BTK 2100/4885ITK 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.